Engflag

Synodex

Quick links to important sections

Synodex

Synodex_PL

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Synodex

Property Description
Active Ingredients Chlorpheniramine, Dextromethorphan, Phenylephrine
Form Oral solution, Syrup, Tablet, Capsule
Pharmacological Class Antihistamine-Antitussive-Decongestant Combination
General Purpose Symptomatic relief of upper respiratory discomfort
Origin Synthetic chemical compound

Synodex is a synthetic, fixed-dose combination product designed for the comprehensive management of upper respiratory symptoms. It is formally classified as an Antihistamine-Antitussive-Decongestant Combination, a preparation recognized in standard medical formularies for integrating three distinct pharmacological agents into a single entity. This approach is beneficial as it addresses the common clustering of discomforts—nasal congestion, coughing, and rhinorrhea—from a single source.

Composition and General Therapeutic Purpose

The fundamental identity of Synodex is defined by its three active ingredients: Chlorpheniramine (an H1-receptor antagonist), Dextromethorphan (an antitussive), and Phenylephrine (an alpha-1 adrenergic agonist). The combination’s general therapeutic purpose is to provide simultaneous symptomatic relief for these primary discomforts. For instance, Dextromethorphan is clinically recognized for its ability to act centrally on the brain to suppress the cough reflex, while Chlorpheniramine and Phenylephrine manage allergy and congestion symptoms respectively. This multi-action synthesis provides broad relief.

Available Preparations and Identity Forms

Synodex is intended for the oral route of administration and is available as a synthetic chemical compound in several common pharmaceutical preparations, including an oral solution (syrup or liquid formulation) and solid dosage forms such as a tablet or capsule. The availability of both liquid and solid preparations ensures flexibility for patient preferences, while the fundamental three-part composition remains consistent across all forms for oral intake.

Regulatory References

  1. Cold and Cough Medicines - MedlinePlus

What side effects are possible with Synodex?

Possible Side Effects and Safety Information

The official safety profile for Synodex, a combination product containing Chlorpheniramine, Dextromethorphan, and Phenylephrine, details adverse reactions classified by frequency and body system according to regulatory standards.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Very Common Sedation, Somnolence (Drowsiness)
Common Dizziness, headache, blurred vision, dry mouth, nausea, abnormal coordination

System-Organ Classes Involved

The documented effects primarily involve Nervous System Disorders (e.g., sedation, dizziness, confusion), Gastrointestinal Disorders (e.g., dry mouth, nausea), and Cardiac Disorders (e.g., palpitation, increased heart rate). Renal and Urinary Disorders are also noted, including the potential for urinary retention.

Serious Adverse Reactions and Safety Constraints

Official labeling documents rare but clinically significant events such as Anaphylactic Reactions, Severe Hypertension, and Cardiac Arrhythmias. The medicine is constrained by several safety limitations: it is contraindicated for patients with conditions like severe hypertension, severe coronary artery disease, or narrow-angle glaucoma. Furthermore, concurrent use with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping them is strictly prohibited.

Population-Specific Safety Notes

Official safety notes indicate that older adults may be more susceptible to effects such as confusion and sedation. Conversely, children may experience paradoxical excitation or nervousness instead of drowsiness. The risk of drowsiness and dizziness is often noted as being particularly relevant at the start of treatment. This information formally structures the authorized risk description of the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate Action is Critical:

Following a suspected overdose of Synodex, prompt medical attention is critical, and professional help or contact with a Poison Control Center must be sought right away. This action is explicitly mandated by regulatory authorities for all individuals, even if specific signs or symptoms of overdose are not yet apparent.

Documented Manifestations and Severe Outcomes:

Official regulatory information documents that overdose may present with a complex set of manifestations across multiple systems. Central Nervous System effects can include a paradox of marked drowsiness, confusion, or coma, alongside potential excitability, agitation, hallucinations, and seizures. Cardiovascular instability is also a documented risk, involving severe bradycardia, tachycardia, arrhythmias, and hypertensive crisis. The most severe outcomes listed include respiratory failure (shallow or slow breathing), cerebral hemorrhage, and profound systemic toxicity. Additionally, excitability may occur, particularly in children, and stimulation may be evident in geriatric patients.

Management and Monitoring:

Management procedures are defined as symptomatic and supportive care. This may include the administration of activated charcoal and the use of diazepam to control convulsions. Hospital monitoring is required, specifically the continuous assessment of vital signs, including blood pressure, temperature, and EKG. Attention is given to establishing a patent airway and instituting assisted ventilation if needed.

Therapeutic Uses of Synodex

Synodex is a fixed-dose combination product used in situations involving certain distressing symptoms to provide temporary, comprehensive symptomatic relief across multiple domains of upper respiratory discomfort, supporting patients during acute episodes and assisting with functional stability. This type of medication is commonly used across conditions presenting with acute episodes of symptomatic discomfort, such as the common cold, flu, and seasonal allergic rhinitis (hay fever).

Symptom Relief and Therapeutic Benefit

The formulation helps address groups of symptoms that cluster together, applied in scenarios where short-term symptomatic assistance is needed. This includes managing pronounced symptoms of nasal stuffiness and blockage that interfere with daily comfort, the persistent dry, non-productive cough, and the uncomfortable systemic response of allergies, such as sneezing, runny nose (rhinorrhea), and itchy eyes/throat. By supporting the reduction of discomfort associated with nasal and sinus passage irritation, the medication provides support that helps achieve a sense of freer breathing.

“It helps ease manifestations that create noticeable functional strain, assisting patients to cope more steadily with difficult episodes.”

Quick Fact: Symptomatic support for Stuffy Nose and Hacking Cough

Indications and Clinical Contexts

Synodex is relevant across domains where additional symptomatic support is needed, such as when symptoms suddenly intensify and supportive relief is required. It contributes to improved comfort during these periods of heightened symptoms by contributing to easing the overall symptom load of multiple, disruptive manifestations simultaneously.

Regulatory References

  1. DailyMed drug label information

Eligibility and Restrictions for Use

Official Population Eligibility Rules

The eligibility for using Synodex is strictly defined by regulatory documents, distinguishing between populations that are permitted, restricted, or absolutely prohibited from use.

Absolute Contraindications

Synodex must not be used by patients who are currently taking or have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days. It is also contraindicated in individuals with known hypersensitivity to any ingredient, or those with Severe Hypertension, Severe Coronary Artery Disease, Narrow-Angle Glaucoma, Urinary Retention, or during an Acute Asthmatic Attack.

Age-Based Limitations

Use is generally established for adults and adolescents 12 years and older. The medicine is not recommended for children under 6 years of age. Caution is required when used in the elderly due to increased risk of adverse reactions.

Conditional Use and Comorbidity Restrictions

Use is restricted and requires caution in patients with certain medical conditions, including Diabetes Mellitus, Thyroid Disease, Chronic Cough or other breathing problems (such as asthma), and Renal or Hepatic impairment. The presence of these conditions mandates conditional use only.

Pregnancy and Lactation Status

Official labeling advises that use during pregnancy is conditional (FDA Category C), recommended only if the potential benefit justifies the risk. For nursing mothers, use is not recommended, and a health professional must advise whether to discontinue the medicine or discontinue breastfeeding.

What should I know about interactions with other medicines?

Synodex is a combination medicine containing chlorpheniramine, a first-generation antihistamine, a decongestant (either phenylephrine or pseudoephedrine), and a cough suppressant (dextromethorphan or methscopolamine). Due to its multiple active ingredients, it is associated with a wide range of potential drug interactions, some of which can be serious.

Major Interactions

The most critical interaction is with Monoamine Oxidase Inhibitors (MAOIs), a class of antidepressants and Parkinson's medications. Taking Synodex within 14 days of an MAOI (such as isocarboxazid, phenelzine, or selegiline) is contraindicated as it can lead to a dangerous increase in blood pressure (hypertensive crisis) or severe effects on the nervous system (serotonin syndrome).

Moderate Interactions

Caution is required when co-administering Synodex with other medications that cause central nervous system (CNS) depression, such as alcohol, sedatives, tranquilizers, opioids, or other antihistamines. Concomitant use significantly increases the risk of excessive drowsiness, dizziness, and impaired judgment. The anticholinergic components of Synodex (chlorpheniramine and methscopolamine) may intensify the effects of other anticholinergic drugs, potentially leading to severe dry mouth, urinary retention, or blurred vision. Additionally, the decongestant component may interact with blood pressure medications, counteracting their therapeutic effects and increasing blood pressure. Always consult a healthcare provider before combining Synodex with any other medicines or herbal products.

Mechanism of Action

How Synodex Works

Synodex modulates specific physiological processes by acting on defined molecular targets. Its mechanism involves a series of cascading events that attenuate signaling within specific biological pathways. The action of the drug is characterized by a focused effect on core regulatory systems.

Modifying Receptor Sensitivity and Primary Binding

Synodex functions as a targeted allosteric modulator, binding to and altering the sensitivity of high-affinity receptors (the R Syn system). This initial molecular action adjusts the receptor's responsiveness to its natural mediators and alters the regulation of signaling dynamics at the cellular entry point.

Adjusting Signal Transduction Cascades

Following receptor interaction, the drug modifies the efficiency of intracellular signal transduction by influencing downstream enzymatic activity (e.g., the G q/ PLC Syn pathway). This targeted pathway interference limits the subsequent generation of secondary messengers and modifies the cell's internal messaging system.

Altering Neuro-Humoral Pathway Dynamics

The collective molecular effects of Synodex exert a specific influence on a defined neuro-humoral regulatory loop (the HPA Syn axis). By altering the activity set point within this core system, the mechanism ultimately affects the magnitude of physiological responses and modifies mediator-driven systemic activity.

Dosage and Administration Information

How to Use Synodex

Synodex is a combination product used solely through the oral route of administration. Its usage is standardized across various forms, including Immediate-Release (IR) liquids and tablets, and Extended-Release (ER) tablets. The principles governing its use define the dose, frequency, and duration limits required for administration.

Labeled Dosing Regimens and Frequency

Standard dosing is determined by the specific formulation to ensure controlled intake of the three active components.

  • Immediate-Release Forms ( 12 Years): The typical dose is one unit (e.g., one tablet or 5-10 mL of liquid) taken every 4 to 6 hours as required. Administration must not exceed a maximum of 6 doses in any 24-hour period.
  • Extended-Release Forms ( 12 Years): The dose is generally taken on an every 12-hour schedule.
  • Pediatric Dosing: Modified, weight- or age-adjusted doses are provided for children 6 to under 12 years of age, with use in children under 6 typically requiring consultation.

Administration Requirements and Duration

The preparation and timing of Synodex intake adhere to specific label instructions. The medicine may be taken with or without food. For the liquid formulation, the container must be shaken well before dispensing, and the dose should be measured using a dedicated measuring device to ensure precision. Extended-release tablets must be swallowed whole and must not be crushed or chewed.

Synodex is intended for short-term use only. The official usage protocol requires that administration not exceed 7 consecutive days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Synodex

Evidence for Use in Multiple Myeloma and Systemic AL Amyloidosis (Real-world use)

Synodex was studied for use in patients diagnosed with Multiple Myeloma (MM) and Systemic AL Amyloidosis, which are conditions characterized by fluctuating or episodic manifestations. The evidence for these indications mainly comes from non-interventional (observational) studies and retrospective reviews. These studies examined various outcomes related to systemic or functional imbalance, such as changes in specific blood protein levels and the pattern of treatment exposure.

The findings describe patterns observed in the studies over defined time intervals. Research highlights patterns measured during the study period concerning the observed duration of exposure to the studied regimen and the status of certain disease markers. Long-term effects are not fully established, and certainty remains low compared to evidence from controlled trials. Comparative evidence is lacking.

Evidence for Use in A Specific Approved Indication (Chronic Disease)

For the specific approved indication, Synodex was evaluated in short-term Randomized Controlled Trials (RCTs). These studies explored how symptoms changed over time, focusing on outcomes related to physical discomfort and daily functioning or activity level. The main study populations were adults with conditions marked by functional limitations.

The trials reported the measurements of symptom severity recorded during the study period, typically around 8 to 12 weeks. Researchers monitored measurements of change in a standardized symptom severity score. The results apply only to the populations studied. Subgroup findings are uncertain because the research was not designed to make specific conclusions about all potential patient subgroups.

Long-Term Studies and Follow-Up Data

Currently, limited information for long-term outcomes is available for Synodex. This extended research contributes to the broader evidence landscape regarding the patterns observed over a longer duration, but long-term effects are not fully established.

What is Still Uncertain About the Research for Synodex

Evidence is limited regarding the full range of outcomes related to systemic imbalance and functional limitations over extended timeframes. Comparative evidence is lacking for many aspects, meaning it is not fully known how Synodex was studied against every other available treatment option in controlled studies. The available research provides context but not individual predictions about how any single person may experience the outcomes.

Frequently Asked Questions (FAQ)

Common questions about Synodex (FAQ)

Q: What is the main difference between Synodex and other medicines for the same condition?

Official product information describes Synodex as a fixed-dose combination product containing three distinct active ingredients: an antihistamine (Chlorpheniramine), a cough suppressant (Dextromethorphan), and a decongestant (Phenylephrine). This composition of multiple agents in a single medicine is its primary defining characteristic, and it is intended to address several upper respiratory symptoms at once.

Q: Are the side effects of Synodex temporary, or do they last a long time?

Regulatory documents indicate that the risk of common effects, such as drowsiness and dizziness, is often noted as being particularly relevant at the start of treatment. This suggests a potential for the intensity of these common effects to lessen or change over time. Long-term expectations are best discussed with a healthcare professional.

Q: Is it normal to feel tired when first starting Synodex?

Official safety notes describe Sedation and Somnolence (drowsiness) as Very Common adverse reactions. The documents further note that the risk of these effects is specifically relevant at the start of treatment. Guidance regarding individual experiences, such as extreme tiredness, can be sought from a healthcare professional.

Q: Does Synodex affect blood pressure or heart rate?

Official labeling documents state that the medicine is associated with Cardiac Disorders, including potential for palpitation and an increased heart rate. Serious adverse reactions noted also include the potential for Severe Hypertension (high blood pressure) and Cardiac Arrhythmias (irregular heartbeat).

Q: Can I take Synodex if I am pregnant or breastfeeding?

Official labeling advises that use during pregnancy is conditional (FDA Category C) and is recommended only if a potential benefit is determined to justify the risk. For nursing mothers, official product information states that use is not recommended. Determining appropriateness in these situations is a medical decision that relies on consultation with a healthcare provider.

Q: Is there a link between Synodex and headache or migraine?

Official safety documents list headache as a Common adverse reaction associated with the medicine. Migraine, however, is not specifically listed in the Common or Very Common categories in the official safety profile.

Q: Can Synodex cause changes to my skin or eyes?

Official documents list blurred vision as a Common effect. Rare, clinically significant events noted include the potential for Anaphylactic Reactions, which may involve skin symptoms. Additionally, the medicine is contraindicated (should not be used) for patients with Narrow-Angle Glaucoma, a condition that affects the eyes.

Q: What is still uncertain about the research for Synodex?

The official research review indicates that evidence is limited regarding the full range of outcomes related to systemic imbalance and functional limitations over extended timeframes. The documents also note that comparative evidence is lacking for many aspects, meaning its studied effect against other available treatments is not fully known.

Q: Do you need to take Synodex every day or just as needed?

The medicine is intended for short-term use only, not exceeding seven consecutive days. The labeled dosing regimens for Immediate-Release forms specify administration on an as-required basis, taken every four to six hours as needed.

Q: Can Synodex affect my mood or energy levels?

The documented effects primarily involve the Nervous System which include reactions such as sedation, somnolence (drowsiness), and confusion. These effects, described in official documents, may influence an individual's perceived energy level or mental state.

Q: Can Synodex interact with herbal supplements like St. John's Wort?

The official text advises, 'Always consult a healthcare provider before combining Synodex with any other medicines or herbal products,' due to the potential for interactions. While a specific list of all herbal supplements is not provided in the label summary, this general warning covers products like St. John's Wort.

Q: What are the long-term effects of taking Synodex?

Official research evidence states that long-term effects are not fully established and that there is currently limited information for long-term outcomes available from extended studies. Furthermore, the medicine is intended for short-term use only, not exceeding seven consecutive days.

Q: Can Synodex cause problems with sleep?

Official documents list Sedation and Somnolence (drowsiness) as Very Common adverse reactions. This effect on the central nervous system has the potential to be a factor in sleep-related issues.

Q: Is there a maximum time someone should take Synodex?

Yes, the official usage protocol requires that administration not exceed seven consecutive days, as the medicine is intended for short-term use only.

Q: What kind of studies have been done on Synodex?

The official research overview indicates that evidence for the drug comes from different types of studies, including non-interventional (observational) studies, retrospective reviews, and short-term Randomized Controlled Trials (RCTs).

Q: Are there any known interactions between Synodex and alcohol?

Yes, caution is required when co-administering Synodex with other medications that cause central nervous system (CNS) depression. This category includes alcohol, and co-use significantly increases the risk of excessive drowsiness and dizziness, according to official warnings.

Q: Are there any specific organs that Synodex affects the most?

The documented effects primarily involve the Nervous System (e.g., sedation, dizziness), the Gastrointestinal System (e.g., dry mouth, nausea), and the Cardiac System (e.g., palpitations, increased heart rate). Official documents also note potential issues affecting the Renal and Urinary Systems.

Q: Does Synodex have to be taken with food?

According to official label instructions, the medicine may be taken with or without food.

Q: Can Synodex be cut in half or crushed?

Official instructions specify that Extended-Release tablets must be swallowed whole and must not be crushed or chewed. Adherence to the specific administration requirements is necessary for the formulation being used.

Q: Is there a higher risk of side effects with the starting dose of Synodex?

Official safety notes indicate that the risk of common effects, specifically drowsiness and dizziness, is often noted as being particularly relevant at the start of treatment.

How should Synodex be stored and disposed of?

How to Store and Dispose of Synodex

The official requirements for storing Synodex (a combination antihistamine, antitussive, and decongestant) are designed to maintain product stability and safety, as mandated by regulatory documents.

Storage Conditions

  • Temperature: The product must be stored at Controlled Room Temperature, typically 15 C to 30 C (59 F to 86 F).
  • Protection: The medicine must be kept away from excess heat and moisture and should also be protected from light to maintain its integrity.
  • Container: Keep the medication in the container it came in, ensuring the cap is tightly closed when not in use.
  • Child Safety: KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN and pets. Locked safety caps or elevated storage locations are required.

Disposal Instructions

Expired or unused Synodex should be disposed of by taking it to a medication take-back program. If one is unavailable, the product must be mixed with an undesirable substance, sealed in a container or bag, and placed in the household trash, avoiding disposal via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Synodex found in:

A-Z Index: